OTTAWA, April 8 /PRNewswire-FirstCall/ - Hard to Treat
Diseases (HTDS; http://www.htdsmedical.com/) Collagenna Skin Care
Products will be officially presented to the Swiss Pharmaceutical
and Health Care Sector at the upcoming Health Pharma Bern Expo
April 10/11, 2010. http://www.healthandpharma.ch/
Collagenna Skin Care Products' exclusive distributor Alphaderm
Body and Wellness, www.alphaderm.ch will be exhibiting at the show.
Collagenna's Products will be front and center. As well,
Alphaderm's CEO, Irene Grimm has
been added to the list of speakers. She will present several public
presentations to the audience attending the exposition. The
Collagenna Skin Care line to the participants will be showcased.
Products will be available for purchase in the Alphaderm/Collagenna
booth.
Michael Arnkvarn, CEO of Collagenna Skin Care Products stated,
"We are very excited about the feedback that we have been receiving
from the Swiss market. The products are giving the expected results
and Alphaderm is ordering on a regular basis. In fact, they have
hired an experienced skin representative who will be dedicated to
the promotion of the Collagenna Skin Care line. This exposition
will allow us to maintain the momentum that the initial sales
efforts have created. Alphaderm's main market is with hotels, spas
and skin care clinics but we both agree that we would entertain
some distribution via retail outlets such as pharmacies and this
will be an excellent opportunity to test the waters."
In other news Michael Arnkvarn, CEO of Collagenna Skin Care
Products invites all shareholders and followers of HTDS to attend
the company shareholder Expo in Toronto April
9th at the Marriott Airport hotel. Shortly the company will
be making an update on its recently announced share buyback program
and the progress made to date.
The company reminds our shareholders and followers that the
company does not subscribe to the PinkSheets.Com Filing Service.
Its IR company web site section "NEWS and FILING" TAB
www.minamargroup.net should be reviewed by its followers for
further updates on this and other business matters. Non-newsworthy
events are not press released however posted on this separate
support sites to keep our followers advised of day-to-day events,
and the company corporate web site. For any matters relating to
retail investor queries or to send us the company directly a
message please click on the "INVESTOR SUPPORT" TAB or this direct
link www.minamargroup.net/helpdesk.
To be included in company's email database for press releases,
industry updates, and non-weekly activity at the company that may
or may not be news released, please subscribe or opt in mailer at
www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future
expectations, plans, prospects or performance of Hard to Treat
Diseases, Inc. that constitute forward-looking statements for
purposes of the safe harbor Provision's under the Private
Securities Litigation Reform Act of 1995. The words or phrases "can
be," "expects," "may affect," "believed," "estimate," "project,"
and similar words and phrases are intended to identify such
forward-looking statements. HTDS Corporation cautions you that any
forward-looking information provided by or on behalf of Hard to
Treat Diseases, Inc. is not a guarantee of future performance. None
of the information in this filing constitutes or is intended as an
offer to sell securities or investment advice of any kind. Hard to
Treat Diseases, Inc.'s actual results may differ materially from
those anticipated in such forward-looking statements as a result of
various important factors, some of which are beyond Hard to Treat
Diseases, Inc.'s control. In addition to those discussed in Hard to
Treat Diseases, Inc.'s press releases, public filings, and
statements by Hard to Treat Diseases, Inc.'s management, including,
but not limited to, Hard to Treat Diseases, Inc.'s estimate of the
sufficiency of its existing capital resources, Hard to Treat
Diseases, Inc.'s ability to raise additional capital to fund future
operations, HTDS Corporation's ability to repay its existing
indebtedness, the uncertainties involved in estimating market
opportunities and, in identifying contracts which match Hard to
Treat Diseases, Inc.'s capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which
such statements were made. Hard to Treat Diseases, Inc. does not
undertake any obligation to publicly update any forward-looking
statement to reflect events or circumstances after the date on
which any such statement is made or to reflect the occurrence of
unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only,
please contact medicalinfo@htdsmedical.com; For any corporate
matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
